10-Q: TransMedics Soars with Q3 Profit, Revenue Growth

TransMedics Group reports significant revenue and net income growth for Q3 and the first nine months of 2025, driven by its OCS and NOP programs.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 32.2% to $143.8 million, up from $108.8 million in the prior year period.
• Net income for the third quarter of 2025 surged by 478.6% to $24.3 million, compared to $4.2 million in the same period last year.
• Diluted earnings per share (EPS) for Q3 2025 was $0.66, a substantial increase from $0.12 in Q3 2024.
• For the nine months ended September 30, 2025, total revenue grew by 39.0% to $444.7 million, up from $319.9 million in the prior year period.
• Net income for the first nine months of 2025 increased by 196.9% to $84.9 million, compared to $28.6 million in the same period last year.
• Diluted EPS for the nine months ended September 30, 2025, was $2.28, up from $0.81 in the prior year period.
• Cash and restricted cash stood at $466.7 million as of September 30, 2025, an increase from $337.2 million at December 31, 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $158.3 million, significantly higher than $29.1 million in the prior year period.
• The company identified a material weakness in its internal control over financial reporting related to inventory movement within its manufacturing network.
• A class action lawsuit, consolidated as Jewik v. TransMedics Group, Inc., et al., is ongoing, alleging misstatements and omissions that artificially inflated stock price during February 28, 2023, and January 10, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated exceptional financial performance with significant revenue and net income growth, improved gross margins, and strong cash flow from operations. Strategic investments in manufacturing and logistics are positive for future expansion. However, the identified material weakness in internal controls and ongoing class action litigation introduce elements of risk and uncertainty, preventing a perfect score.

Positives

• Achieved substantial revenue growth of 32.2% in Q3 2025 and 39.0% for the nine months ended September 30, 2025, driven by increased sales of OCS Liver and OCS Heart disposable sets and higher NOP usage.
• Reported significant net income growth of 478.6% in Q3 2025 ($24.3 million) and 196.9% for the nine months ended September 30, 2025 ($84.9 million).
• Improved overall gross margin to 59% in Q3 2025 (from 56% in Q3 2024) and 61% for the nine months ended September 30, 2025 (from 59% in 9M 2024), primarily due to increased efficiencies in transplant logistics.
• Generated strong net cash provided by operating activities of $158.3 million for the nine months ended September 30, 2025, a significant increase from $29.1 million in the prior year.
• Maintained a healthy cash balance of $466.2 million as of September 30, 2025, which is believed to be sufficient to fund operations, capital expenditures, and debt service for at least the next 12 months.
• Strategic expansion into Italy with the purchase of land in July 2025 for a new design center of excellence and manufacturing facility, aiming to support next-generation OCS technology and international supply.
• Acquired a fixed-wing aircraft in October 2025 for $14.5 million to enhance the National OCS Program's aviation transportation services.
• Recognized an income tax benefit of $1.3 million in Q3 2025 due to the favorable impact of the One Big Beautiful Bill Act (OBBBA) on its annual effective tax rate.

Negatives

• Identified a material weakness in internal control over financial reporting, specifically regarding effective controls over inventory movement within the manufacturing network.
• Ongoing class action lawsuits alleging misstatements and omissions that artificially inflated the company's stock price during the Class Period (February 28, 2023, to January 10, 2025), with an uncertain outcome.
• Product gross margin slightly decreased to 79% in Q3 2025 from 80% in Q3 2024, although it remained stable at 80% for the nine-month period.
• Revenue from OCS Lung in the United States decreased to $3.7 million in Q3 2025 from $3.7 million in Q3 2024, and to $11.5 million in 9M 2025 from $12.7 million in 9M 2024.
• Revenue from OCS Lung in all other countries decreased to $1.2 million in 9M 2025 from $1.6 million in 9M 2024.
• Interest income and other income (expense), net, decreased by $1.8 million for the nine months ended September 30, 2025, primarily due to lower yields on cash balances.

Risks

• Fluctuation of financial results from quarter to quarter due to unpredictable timing of organ transplant procedures and availability of donor organs/surgeons.
• Ability to attract, train, and retain key personnel, including pilots for aviation transportation services.
• Existing and any future indebtedness, including the ability to comply with affirmative and negative covenants under credit agreements.
• Ability to sustain profitability, as the company only recently achieved it prior to 2024.
• Need to raise additional funding and the ability to obtain it on favorable terms, or at all, which could lead to delays or termination of programs if funding is not secured.
• Ability to use net operating losses and research and development credit carryforwards, which may be subject to annual limitations under Sections 382 and 383 of the Internal Revenue Code.
• Material weakness in internal control over financial reporting regarding inventory movement, which could adversely affect the ability to record, process, summarize, and report financial information.
• Dependence on the success of the Organ Care System (OCS) technology.
• Ability to expand access to the OCS through the National OCS Program (NOP).
• Ability to improve the OCS platform, including developing next-generation products or expanding into new indications.
• Ability to scale manufacturing and sterilization capabilities to meet increasing demand.
• Rate and degree of market acceptance of the OCS.
• Ability to educate patients, surgeons, transplant centers, and payors on OCS benefits.
• Dependence on a limited number of customers for a significant portion of revenue.
• Ability to maintain regulatory approvals or clearances for OCS products in the United States, European Union, and other jurisdictions.
• Ability to adequately respond to FDA or other competent authorities' follow-up inquiries in a timely manner.
• Impact of healthcare policy changes, including legislation or administrative actions affecting the U.S. healthcare system, Organ Procurement and Transplantation Network (OPTN), or the FDA.
• Performance of third-party suppliers and manufacturers.
• Reliance on third parties for donor organ transport and the ability to maintain and grow transplant logistics capabilities to reduce this dependence.
• Ability to maintain Federal Aviation Administration (FAA) or other regulatory licenses or approvals for aircraft transportation services.
• Price increases of product components and maintenance, parts, and fuel for aircraft.
• Timing or results of post-approval studies and any clinical trials for the OCS.
• Attacks against information technology infrastructure.
• Economic, political, and other risks associated with foreign operations.
• Ability to protect, defend, maintain, and enforce intellectual property rights and avoid infringement allegations.
• Pricing of the OCS and reimbursement coverage in the United States and internationally.
• Regulatory developments in various jurisdictions.
• Impact of current or future U.S. government shutdowns on regulatory agencies and aviation services.
• Extent and success of competing products or procedures.
• Ability to service 1.50% convertible senior notes due 2028.
• Impact of any product recalls or improper use of products.
• Uncertainty in estimates regarding revenue, expenses, and needs for additional financing.
• Legal proceedings, specifically class action lawsuits, which could have an adverse impact on reputation, business, financial condition, and divert management attention.
• A prolonged shutdown of the U.S. federal government could adversely affect business, financial condition, operating results, cash flows, and prospects due to disruptions at regulatory agencies (FDA, FAA, SEC) and potential staffing shortages (e.g., air traffic controllers).

Future Outlook

The company expects operating and capital expenditures to increase as it focuses on growing commercial sales in the United States and select non-U.S. markets, expanding its commercial team, growing the National OCS Program (NOP) including transplant logistics capabilities, scaling manufacturing and sterilization operations, developing the next generation OCS, and continuing research, development, and clinical trial efforts. It also plans to seek regulatory clearance for new products and product enhancements, including additional indications or other organs. The company believes its existing cash will be sufficient to fund operations, capital expenditures, and debt service for at least the next 12 months, but acknowledges the need for potential additional funding which may not be available on favorable terms.

Management Comments

• "We believe that our existing cash of $466.2 million as of September 30, 2025 will be sufficient to fund its operations, capital expenditures, and debt service payments for at least the next 12 months following the filing of this Quarterly Report on Form 10-Q."
• "We expect our operating and capital expenditures will continue to increase as we focus on growing commercial sales of our products in both the United States and select non-U.S. markets, including growing our commercial team, which will pursue increasing commercial sales of our OCS products; growing our NOP, including by maintaining and growing our transplant logistics capabilities, including hiring training and retaining pilots to scale our aviation transportation operations, to support our NOP and reduce dependence on third party transportation, including by means of the acquisition, maintenance or replacement of fixed-wing aircraft or other acquisitions, joint ventures or strategic investments; scaling our manufacturing and sterilization operations; developing the next generation OCS; continuing research, development and clinical trial efforts; seeking regulatory clearance for new products and product enhancements, including additional indications or other organs, in both the United States and select non-U.S. markets; and operating as a public company."
• "Management, with the oversight of the audit committee of our board of directors, is in the process of assessing and finalizing its plan for remediation for the material weakness described above. We intend to remediate this material weakness as soon as possible, and we have begun assessing our design of internal controls to ensure the movement of inventory is timely and accurately recorded throughout the course of the year."

Industry Context

TransMedics operates in the rapidly evolving medical device industry, specifically in organ transplant therapy, which is undergoing a paradigm shift from static organ preservation to dynamic warm perfusion. The company's growth is influenced by initiatives from the U.S. Department of Health and Human Services Health Resources and Services Administration (HRSA) to improve the Organ Procurement and Transplantation Network (OPTN), including a multi-vendor model, the impact of which on the company's NOP is currently uncertain. The global economic environment, including inflation, supply chain disruptions, and tariffs, continues to pose risks to raw material costs, product pricing, and overall demand.

Corporate Governance

Legal Proceedings

• A consolidated class action lawsuit, Jewik v. TransMedics Group, Inc., et al., was filed against the company and certain current/former officers in the U.S. District Court for the District of Massachusetts. The complaint alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, seeking unspecified damages on behalf of investors who purchased shares between February 28, 2023, and January 10, 2025. The lawsuit claims purported misstatements and omissions in the 2022 Annual Report, earnings calls, and other public statements artificially inflated the common stock price. Defendants filed a motion to dismiss on October 7, 2025, with responses due in November and December 2025. The company is unable to predict the outcome or reasonably estimate a range of possible losses at this time.

Related Party Transactions

• Dr. Amira Hassanein, sister of President and CEO Dr. Waleed Hassanein, serves as Product Director for the OCS Lung program. She received approximately $0.2 million in total compensation for the three months ended September 30, 2025, and $0.7 million for the nine months ended September 30, 2025.

Stakeholder Impact

• **Shareholders**: Positive financial results and strategic growth initiatives are beneficial, but the material weakness in internal controls and ongoing class action lawsuit introduce uncertainty and potential risk. A director's 10b5-1 plan for selling shares may be noted.
• **Employees**: Increased headcount and compensation, including stock-based compensation, indicate growth and investment in the workforce. The 401(k) matching program is a positive benefit.
• **Customers**: Continued expansion of the OCS and NOP, along with plans for a new manufacturing facility in Italy, suggest improved service and product availability, particularly for international customers.
• **Suppliers**: The company's dependence on a limited number of sole or single-source suppliers for components and sterilization services poses a risk to supply chain stability.
• **Creditors**: The company is in compliance with all financial covenants of the CIBC Credit Agreement, indicating good standing with its lenders. The ability to service convertible senior notes is also a factor.

Next Steps

• Remediate the identified material weakness in internal control over financial reporting related to inventory movement.
• Continue to grow commercial sales of OCS products in the United States and select non-U.S. markets.
• Expand the National OCS Program (NOP), including maintaining and growing transplant logistics capabilities and acquiring additional fixed-wing aircraft.
• Scale manufacturing and sterilization operations to meet increasing demand.
• Develop the next generation OCS technology platform.
• Continue research, development, and clinical trial efforts.
• Seek regulatory clearance for new products and product enhancements, including additional indications or other organs.
• Construct the design center of excellence and new manufacturing facility for disposable products in Mirandola, Italy.
• Await the court's ruling on the motion to dismiss the consolidated class action lawsuit.

Key Dates

Recommendation

The company's Q3 and year-to-date 2025 financial results demonstrate exceptional growth across revenue, net income, and operating cash flow, significantly outperforming prior periods. The expansion of the OCS and NOP, coupled with strategic investments in manufacturing capacity in Italy and aviation logistics, positions the company for continued market penetration and operational efficiency. While the identified material weakness in internal controls and ongoing class action litigation present risks, the fundamental business performance and strategic trajectory are very strong. The company's ability to generate substantial profits and cash, along with its clear growth strategy in a high-impact medical technology sector, makes it an attractive investment. The risks, while notable, appear manageable in the context of the robust operational and financial momentum.

Keywords

Organ Care System, OCS, Organ Transplant, Medical Technology, National OCS Program, NOP, TransMedics, TMDX, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Income, Profitability, Medical Device, Biotechnology, Healthcare, Transplant Logistics, Aviation Services, Manufacturing Facility, Internal Controls, Class Action Lawsuit